DS
RYTM icon

David Shaw’s Rhythm Pharmaceuticals RYTM Stock Holding History

David Shaw’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$1.23M – 5085
2022
Q3 		$1.23M Buy
+50,000
New +$930K ﹤0.01% 3439

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

David Shaw's RYTM Position: Q2 2026 in Review

David Shaw reduced its Rhythm Pharmaceuticals (RYTM) stake by 7.6% in Q2 2026, selling an estimated $225K and leaving 30,168 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

David Shaw first reported a position in RYTM in Q2 2018 and has held it in 19 quarters since. The position peaked at $10.4M in Q4 2022. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • David Shaw held 30,168 shares of Rhythm Pharmaceuticals worth $3.35M as of Q2 2026.
  • David Shaw sold 2,484 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $225K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2745 holding.
  • David Shaw first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • David Shaw's Rhythm Pharmaceuticals position peaked at $10.4M in Q4 2022.
  • 300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.